Indication
Chronic Lymphocytic Leukemia (CLL)
1 clinical trial
1 drug
Clinical trial
Dose Optimization Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART-19) in Patients With Relapsed or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Status: Completed, Estimated PCD: 2017-12-13
Drug
Tisagenlecleucel